Arrowhead reports FY2026 results, highlights REDEMPLO growth and sNDA submissionNov 12Quarterly updateArrowhead Pharmaceuticalsplozasiran
Arrowhead's two Phase 3 plozasiran SHTG trials both show completed status this weekOct 9Weekly roundup, 4 itemsARO-INHBEArrowhead PharmaceuticalsUpdated
Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal dealAug 4Quarterly updateArrowhead Pharmaceuticalsplozasiran